OPKO Health, Inc.

NasdaqGS:OPK Stock Report

Market Cap: US$1.0b

OPKO Health Future Growth

Future criteria checks 0/6

OPKO Health is forecast to grow earnings and revenue by 43.3% and 6.8% per annum respectively while EPS is expected to grow by 41.7% per annum.

Key information

43.3%

Earnings growth rate

41.7%

EPS growth rate

Healthcare earnings growth20.8%
Revenue growth rate6.8%
Future return on equityn/a
Analyst coverage

Good

Last updated13 Nov 2024

Recent future growth updates

OPKO Health, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Nov 09
OPKO Health, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Recent updates

OPKO Health, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Nov 09
OPKO Health, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Not Enough To Keep OPKO Health Flying

Aug 28

OPKO Health, Inc. (NASDAQ:OPK) Not Flying Under The Radar

Dec 30
OPKO Health, Inc. (NASDAQ:OPK) Not Flying Under The Radar

Is OPKO Health (NASDAQ:OPK) A Risky Investment?

Oct 03
Is OPKO Health (NASDAQ:OPK) A Risky Investment?

OPKO Health, Inc.'s (NASDAQ:OPK) 28% Share Price Surge Not Quite Adding Up

Jul 24
OPKO Health, Inc.'s (NASDAQ:OPK) 28% Share Price Surge Not Quite Adding Up

Would OPKO Health (NASDAQ:OPK) Be Better Off With Less Debt?

Jun 07
Would OPKO Health (NASDAQ:OPK) Be Better Off With Less Debt?

Is OPKO Health (NASDAQ:OPK) Using Too Much Debt?

Jan 04
Is OPKO Health (NASDAQ:OPK) Using Too Much Debt?

OPKO Health: Assessing If Significant Potential Can Be Realized

Sep 15

OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt

Sep 05
OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt

OPKO Health: 14%+ Short Interest Means More Volatility Over The Near Term

Jun 21

OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt

Apr 29
OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt

OPKO Health: A Great Long-Term Investment In Health

Apr 05

Earnings and Revenue Growth Forecasts

NasdaqGS:OPK - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026734-7012N/A3
12/31/2025685-218-17N/A6
12/31/2024685-159-183N/A6
9/30/2024711-134-200-177N/A
6/30/2024716-243-86-67N/A
3/31/2024800-252-59-41N/A
12/31/2023863-189-44-28N/A
9/30/2023867-208-41-22N/A
6/30/2023868-209-110-87N/A
3/31/2023913-291-120-98N/A
12/31/20221,004-328-120-95N/A
9/30/20221,220-317-94-69N/A
6/30/20221,426-202-28-4N/A
3/31/20221,559-117-36-8N/A
12/31/20211,775-30638N/A
9/30/20211,868764678N/A
6/30/20211,9107173108N/A
3/31/20211,76912172109N/A
12/31/20201,43531639N/A
9/30/20201,165-114-72-41N/A
6/30/2020966-200-151-128N/A
3/31/2020891-293-182-167N/A
12/31/2019902-315-185-173N/A
9/30/2019899-279-173-161N/A
6/30/2019920-244-181-159N/A
3/31/2019958-191-147-123N/A
12/31/2018990-153-137-109N/A
9/30/2018929-295-112-72N/A
6/30/2018926-303N/A-88N/A
3/31/2018955-314N/A-94N/A
12/31/2017966-305N/A-92N/A
9/30/20171,081-101N/A-64N/A
6/30/20171,133-80N/A-58N/A
3/31/20171,197-48N/A7N/A
12/31/20161,117-48N/A32N/A
9/30/20161,222-10N/A-8N/A
6/30/20161,067133N/A-7N/A
3/31/201675375N/A-84N/A
12/31/2015492-30N/A164N/A
9/30/2015241-85N/A149N/A
6/30/2015118-262N/A159N/A
3/31/201599-244N/A171N/A
12/31/201491-172N/A-90N/A
9/30/201486-135N/A-92N/A
6/30/201487-147N/A-82N/A
3/31/201487-125N/A-64N/A
12/31/201397-115N/A-56N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OPK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OPK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OPK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OPK's revenue (6.8% per year) is forecast to grow slower than the US market (9.1% per year).

High Growth Revenue: OPK's revenue (6.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if OPK's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 07:54
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

OPKO Health, Inc. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael PetuskyBarrington Research Associates, Inc.
Louise ChenCantor Fitzgerald & Co.
Dana FlandersGuggenheim Securities, LLC